Mark Winderlich

2.1k citations

25 papers · 1.6k indexed · h-index 12

Impact in

Immunology and Allergy top 2%
- Cell Adhesion Molecules Research
Neurology top 5%
- Barrier Structure and Function Studies

Papers in ⓘ

Genetics 10
- Chronic Lymphocytic Leukemia Research 10
Pathology and Forensic Medicine 11
- Lymphoma Diagnosis and Treatment 11

Co-authors: Dietmar Vestweber (8 shared papers)Astrid F. Nottebaum (8 shared papers)Giuseppe Cagna (6 shared papers)Urban Deutsch (3 shared papers)Maike Frye (3 shared papers)Alexander Zarbock (3 shared papers)Andre Broermann (4 shared papers)Olena Kamenyeva (3 shared papers)
Journals: Journal of Clinical Oncology (5 papers)The Journal of Experimental Medicine (3 papers)Blood (3 papers)The Journal of Cell Biology (2 papers)Annals of Hematology (1 paper)
Partner nations: Germany United States Italy

In The Last Decade

Mark Winderlich

23 papers receiving 1.6k citations

Peers

Countries citing papers authored by Mark Winderlich

Since Specialization

Citations

This map shows the geographic impact of Mark Winderlich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Winderlich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Winderlich more than expected).

Fields of papers citing papers by Mark Winderlich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Winderlich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Winderlich. The network helps show where Mark Winderlich may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Winderlich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Winderlich Line = papers co-authored together Mark Winderlich links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell–cell and cell–matrix contacts Nature Cell Biology ·Pipsa Saharinen, Lauri Eklund, Juho J. Miettinen, Riikka Wirkkala, Andrey Anisimov, Mark Winderlich, Astrid F. Nottebaum, Dietmar Vestweber, Urban Deutsch, Gou Young Koh, Bjørn R. Olsen, Kari Alitalo	2008	352
2	Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin Nature Immunology ·Florian Wessel, Mark Winderlich, Maren Holm, Maike Frye, Ronmy Rivera-Galdos, Matthias Vockel, Ruth Linnepe, Ute Ipe, Anika Stadtmann, Alexander Zarbock, Astrid F. Nottebaum, Dietmar Vestweber	2014	274
3	Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player Trends in Cell Biology ·Dietmar Vestweber, Mark Winderlich, Giuseppe Cagna, Astrid F. Nottebaum	2008	223
4	VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF The Journal of Experimental Medicine ·Astrid F. Nottebaum, Giuseppe Cagna, Mark Winderlich, Alexander C. Gamp, Ruth Linnepe, Christian Polaschegg, Kristina O. Filippova, Ruth Lyck, Britta Engelhardt, Olena Kamenyeva, M. Gabriele Bixel, Stefan Butz, Dietmar Vestweber	2008	184
5	Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo The Journal of Experimental Medicine ·Andre Broermann, Mark Winderlich, Helena Block, Maike Frye, Jan Rossaint, Alexander Zarbock, Giuseppe Cagna, Ruth Linnepe, Dörte Schulte, Astrid F. Nottebaum, Dietmar Vestweber	2011	157
6	VE-PTP controls blood vessel development by balancing Tie-2 activity The Journal of Cell Biology ·Mark Winderlich, Linda Keller, Giuseppe Cagna, Andre Broermann, Olena Kamenyeva, Friedemann Kiefer, Urban Deutsch, Astrid F. Nottebaum, Dietmar Vestweber	2009	146
7	Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma Annals of Oncology ·Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaïdano, André Goy, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, Kami J. Maddocks, Christian Buske, Sumeet Ambarkhane, Mark Winderlich, Maren Dirnberger‐Hertweck, Roman Korolkiewicz, Kristie A. Blum	2018	101
8	MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial The Lancet Haematology ·Marc S. Raab, Monika Engelhardt, Antje Blank, Hartmut Goldschmidt, Hermine Agis, Igor Wolfgang Blau, Hermann Einsele, Barbara Ferstl, Natalie Schub, Christoph Röllig, Katja Weisel, Mark Winderlich, Janine Griese, Stefan Härtle, Johannes Weirather, Tiantom Jarutat, Christian Peschel, Manik Chatterjee	2020	68
9	A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma Clinical Lymphoma Myeloma & Leukemia ·Manik Chatterjee, Marc S. Raab, Hartmut Goldschmidt, Hermine Agis, Igor Wolfgang Blau, Hermann Einsele, Monika Engelhardt, Barbara Ferstl, Andreas Günther, Christoph Röllig, Katja Weisel, Tiantom Jarutat, Dominika Weinelt, Mark Winderlich, Rainer Boxhammer, Christian Peschel	2017	20
10	Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study Clinical Cancer Research ·Grzegorz S. Nowakowski, Dok Hyun Yoon, Anthea Peters, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Dan Huang, Eva E. Waltl, Mark Winderlich, Nuwan Kurukulasuriya, Sumeet Ambarkhane, Georg Heß, Gilles Salles	2022	16
11	RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma Annals of Hematology ·Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Winderlich, Andrea Sporchia, Nuwan Kurukulasuriya, Raúl Córdoba, Georg Heß, Gilles Salles	2023	14
12	RE-MIND study: A propensity score-based 1:1 matched comparison of tafasitamab + lenalidomide (L-MIND) versus lenalidomide monotherapy (real-world data) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology ·Grzegorz S. Nowakowski, Thomas D. Rodgers, Dario Marino, Maurizio Frezzato, Anna Maria Barbui, Claudia Castellino, Erika Meli, Nathan Fowler, Bruce A. Feinberg, Sascha Tillmanns, Stephan Parche, Guenter Fingerle-Rowson, Mark Winderlich, Sumeet Ambarkhane, Gilles Salles, Pier Luigi Zinzani	2020	11
13	MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study Blood ·Marc S. Raab, Manik Chatterjee, Hartmut Goldschmidt, Hermine Agis, Igor W. Blau, Hermann Einsele, Monika Engelhardt, Barbara Ferstl, Martin Gramatzki, Christoph Röllig, Katja Weisel, Tiantom Jarutat, Dominika Weinelt, Mark Winderlich, Christian Peschel	2018	9
14	A phase 2a, single‐arm, open‐label study of tafasitamab, a humanized, Fc‐modified, anti‐CD19 antibody, in patients with relapsed/refractory B‐precursor cell acute lymphoblastic leukemia Cancer ·Rebecca B. Klisovic, Wing Leung, Wolfram Brugger, Maren Dirnberger‐Hertweck, Mark Winderlich, Sumeet Ambarkhane, Elias Jabbour	2021	8
15	Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study Blood ·Wojciech Jurczak, Pier Luigi Zinzani, Gianluca Gaïdano, André Goy, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, Kami J. Maddocks, Christian Buske, Sumeet Ambarkhane, Mark Winderlich, Maren Dirnberger‐Hertweck, Jan Endell, Kristie A. Blum	2016	6
16	VE-PTP controls blood vessel development by balancing Tie-2 activity The Journal of Experimental Medicine ·Mark Winderlich, Linda Keller, Giuseppe Cagna, Andre Broermann, Olena Kamenyeva, Friedemann Kiefer, Urban Deutsch, Astrid F. Nottebaum, Dietmar Vestweber	2009	5
17	Evaluation of combination therapies with MOR00208, an Fc-enhanced humanized CD19 antibody, in models of lymphoma. Journal of Clinical Oncology ·Mark Winderlich, Daniel Ness, Stefan Steidl, Jan Endell	2012	3
18	Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). Journal of Clinical Oncology ·Wojciech Jurczak, Pier Luigi Zinzani, André Goy, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, Kami J. Maddocks, Christian Buske, Roman Korolkiewicz, Mark Winderlich, Kristie A. Blum	2015	3
19	MOR202 with low-dose dexamethasone (Dex) and in combination with pomalidomide/dex and lenalidomide/dex in relapsed or refractory multiple myeloma (RRMM): Interim analysis of a phase I/IIa dose-escalation study. Journal of Clinical Oncology ·Marc S. Raab, Manik Chatterjee, Hartmut Goldschmidt, Hermine Agis, Igor Wolfgang Blau, Hermann Einsele, Monika Engelhardt, Barbara Ferstl, Martin Gramatzki, Christoph Röllig, Katja Weisel, Tiantom Jarutat, Dominika Weinelt, Mark Winderlich, Rainer Boxhammer, Christian Peschel	2017	3
20	B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase II/III trial. Journal of Clinical Oncology ·Grzegorz S. Nowakowski, David Belada, Lysianne Molina, Kateřina Kopečková, Kamel Laribi, R. del Campo García, Bertrand Coiffier, Wojciech Jurczak, Mathias Rummel, Georg Heß, Andreas Rosenwald, Mark Winderlich, Roman Korolkiewicz, Pier Luigi Zinzani	2017	2

About Mark Winderlich

Mark Winderlich is a scholar working on Genetics, Pathology and Forensic Medicine, Immunology and Allergy, Oncology and Hematology, having authored 25 papers that have together received 1.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (10 papers), CAR-T cell therapy research (10 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Angiogenesis and VEGF in Cancer (6 papers), Multiple Myeloma Research and Treatments (4 papers), Cell Adhesion Molecules Research (3 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Immunology and Allergy (285 citations), Neurology (143 citations), Immunology (352 citations), Cell Biology (253 citations) and Hematology (159 citations). Mark Winderlich has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Dietmar Vestweber, Astrid F. Nottebaum, Giuseppe Cagna, Urban Deutsch, Maike Frye, Alexander Zarbock, Andre Broermann, Olena Kamenyeva, Juho J. Miettinen and Pipsa Saharinen. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Experimental Medicine, Blood, The Journal of Cell Biology and Annals of Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact